InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
3
已披露卖出
0
T+90 胜率
33%
T+90 平均收益
+1.0%
基于 3 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the complete record of transactions filed by Sigal Charles Elliott, 董事. Officer active across 3 companies, notably Vir Biotechnology, Inc.. Aggregated, 11 reports have been recorded. Split: 3 buys · 0 sell. Total volume traded: €172k. History available since 21 May 2021. The latest transaction was filed on 20 May 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Sigal Charles Elliott
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报11 总计
671 股0Common StockSEC:0001178670-26-000042:0
8,000 股0Common StockSEC:0001628280-25-028902:0
775 股0Common StockSEC:0001735276-25-000060:0
8,000 股0Common StockSEC:0001628280-24-026221:0
45,453 股Common StockSEC:0001209191-23-048762:0
6,027 股0Common StockSEC:0001209191-23-031840:0
2,500 股@ US$22.726231.1% 占其流量Common StockSEC:0001209191-23-014673:0
标准退出：2023年5月30日 (T+90)
2,500 股@ US$24.958234.1% 占其流量Common StockSEC:0001209191-23-002507:0
标准退出：2023年4月5日 (T+90)
2,500 股@ US$25.59734.7% 占其流量Common StockSEC:0001209191-23-001932:0
标准退出：2023年4月3日 (T+90)
6,405 股0Common StockSEC:0001209191-22-031959:0
3,374 股0Common StockSEC:0001209191-21-035717:0
11 条申报中的 11 条
About Sigal Charles Elliott
Sigal Charles Elliott is Administrateur at Vir Biotechnology, Inc., ALNYLAM PHARMACEUTICALS, INC. and Surface Oncology, Inc. The file shows 11 filings in total, and across the 11 sampled filings from 2021-05-25 to 2026-05-22, buys total EUR 172474 and sells total EUR 0, with Attribution as the most common transaction nature.
